About Bio-Gene
Bio-Gene is a company based in Melbourne (Australia) founded in 1995. Bio-Gene has raised $4.05 million across 7 funding rounds from investors including U.S. Department of Defense. Bio-Gene offers products and services including Flavocide and Qcide. Bio-Gene operates in a competitive market with competitors including UPL, Terramera, MoA Technology, Vestaron and Micropep, among others.
- Headquarter Melbourne, Australia
- Stage Public
-
Sectors
Chemicals & MaterialsAgriculture
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bio-Gene Technology Ltd
-
Annual Revenue
Not available
-
Net Profit
-$1.7 M (USD)-7.28as on Jun 30, 2025
-
EBITDA
-$2.03 M (USD)-0.15as on Jun 30, 2025
-
Total Equity Funding
$4.05 M (USD)
in 7 rounds
-
Latest Funding Round
$2.1 M (USD), Post-IPO
May 05, 2025
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Bio-Gene
Bio-Gene is a publicly listed company on the ASX with ticker symbol BGT in Australia, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Bio-Gene
Bio-Gene offers a comprehensive portfolio of products and services, including Flavocide and Qcide.
Synthetic molecule for controlling insect pests in crops and storage.
Natural oil product for safe pest management in various applications.
Funding Insights of Bio-Gene
Bio-Gene has successfully raised a total of $4.05M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2.1 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Bio-Gene
Bio-Gene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include U.S. Department of Defense.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Military forces are provided by the U.S. Department of Defense for national security.
|
Locked | Locked | Locked |
Investor details for Bio-Gene
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bio-Gene
Investment portfolio details for Bio-Gene
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Bio-Gene
Detailed financials for Bio-Gene
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bio-Gene Comparisons
Peer comparison for Bio-Gene
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bio-Gene
Bio-Gene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as UPL, Terramera, MoA Technology, Vestaron and Micropep, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sustainable agriculture technologies and solutions are provided to farmers globally.
|
|
| Locked | Locked | Locked |
Plant-based biopesticides are developed for agricultural applications by Terramera.
|
|
| Locked | Locked | Locked |
Plant-based biologicals for weed control in agriculture are developed.
|
|
| Locked | Locked | Locked |
Biological insecticides and pesticides are developed from spider peptides.
|
|
| Locked | Locked | Locked |
Plant-based crop protection products are developed for targeted agricultural applications.
|
Detailed competitors of Bio-Gene
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bio-Gene
Complete news archive for Bio-Gene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bio-Gene
Bio-Gene was founded in 1995 and raised its 1st funding round 21 years after it was founded.
Bio-Gene is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Tim Grogan is the current CEO of Bio-Gene.
Bio-Gene is a funded company, having raised a total of $4.05M across 7 funding rounds to date.
Developing a patent protected product platform as a new class of insecticides. The company is developing two products Qcide and Flavocide. Qcide is developed from oil extracts of Gympie Messmate and is focused on organic insect control and Flavocide is a chemically synthesized product developed as a natural identical molecule to molecules also found in Eucalyptus cloeziana extracts. The company uses beta-triketones to address the problem of insecticide resistance and toxicity. It also owns patents covering the use of beta-triketone insecticides for insect control.
Bio-Gene's top competitors include Terramera, Vestaron and MoA Technology.
Bio-Gene offers Flavocide and Qcide.
Yes, Bio-Gene is publicly traded on ASX under the ticker symbol BGT.
Bio-Gene has 1 investor. Key investors include U.S. Department of Defense.
The ticker symbol of Bio-Gene is BGT on ASX.